Systematic review of mesotherapy: a novel avenue for the treatment of hair loss

References

• Tang Z, Hu Y, Wang J, et al. Current application of mesotherapy in pattern hair loss_ a systematic review. J Cosmet Dermatol. 2022;21(10):1–11. doi: 10.1111/jocd.14900.
   Web of Science ®Google Scholar
• Mysore V. Mesotherapy in management of hairloss – is it of any use. Int J Trichology. 2010;2(1):45–46. doi: 10.4103/0974-7753.66914.
   PubMedGoogle Scholar
• Mammucari M, Maggiori E, Russo D, et al. Mesotherapy: from historical notes to scientific evidence and future prospects. Sci World J. 2020;2020:3542848.
   Google Scholar
• Müller Ramos P, Melo DF, Radwanski H, et al. Female pattern hair loss: therapeutic update. An Bras Dermatol. 2023;S0365-0596:00053–00053.
   Google Scholar
• Issa NT, Kaiser M, Martinez-Velasco A, et al. Alopecia after cosmetic injection procedures: a review. Dermatol Surg. 2022;48(8):855–861. doi: 10.1097/DSS.0000000000003498.
   PubMed Web of Science ®Google Scholar
• Chien Yin GO, Siong-See JL, Wang ECE. Telogen effluvium – a review of the science and current obstacles. J Dermatol Sci. 2021;101(3):156–163. doi: 10.1016/j.jdermsci.2021.01.007.
   PubMed Web of Science ®Google Scholar
• Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349–1364. doi: 10.1007/s40265-016-0629-5.
   PubMed Web of Science ®Google Scholar
• Ramírez-Marín HA, Tosti A. Emerging drugs for the treatment of alopecia areata. Expert Opin Emerg Drugs. 2022;27(4):379–387. doi: 10.1080/14728214.2022.2149735.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Wang T, Polla Ravi S, et al. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol. 2023;37(4):666–679. doi: 10.1111/jdv.18810.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence [Internet]. 2011 [cited 2023 May 24]. Available from: http://www.cebm.net/index.aspx?o=5653.
   Google Scholar
• Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338–345. doi: 10.1159/000510697.
   PubMed Web of Science ®Google Scholar
• Abdallah M, El-Zawahry K, Besar H. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan-Arab League Dermat. 2009;20:137–145.
   Google Scholar
• Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686–693. doi: 10.1111/j.1468-3083.2012.04535.x.
   PubMed Web of Science ®Google Scholar
• Sobhy N, Aly H, El Shafee A, et al. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013;4(1):40–45. doi: 10.7241/ourd.20131.08.
   Google Scholar
• Saceda-Corralo D, Rodrigues-Barata A, Vano-Galvan S, et al. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143–145. doi: 10.4103/ijt.ijt_73_16.
   PubMedGoogle Scholar
• Do Nascimento IJB, Harries M, Rocha VB, et al. Effect of oral minoxidil for alopecia: systematic review. Int J Trichology. 2020;12(4):147–155. doi: 10.4103/ijt.ijt_19_20.
   PubMedGoogle Scholar
• Sung CT, Juhasz MLW, Choi FD, et al. The efficacy of topical minoxidil for non-scarring alopecia: a systematic review. J Drugs Dermatol. 2019;18:155–160.
   PubMed Web of Science ®Google Scholar
• Uzel BPC, Takano GHS, Chartuni JCN, et al. Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo-controlled trial. Dermatol Ther. 2021;34:e14622.
   PubMed Web of Science ®Google Scholar
• Azam MH, Morsi HM. Comparative study between 2% minoxidil topical spray vs. Intradermal injection (mesotherapy) for treatment of androgenetic alopecia in female patients: a controlled, 4-month randomized trial. Egyptian Dermatol Online J. 2010;6:5.
   Google Scholar
• Anitua E, Pino A, Martinez N, et al. The effect of plasma rich in growth factors on pattern hair loss: a pilot study. Dermatol Surg. 2017;43(5):658–670. doi: 10.1097/DSS.0000000000001049.
   PubMed Web of Science ®Google Scholar
• Kieb M, Sander F, Prinz C, et al. Platelet-Rich plasma powder: a new preparation method for the standardization of growth factor concentrations. Am J Sports Med. 2017;45(4):954–960. doi: 10.1177/0363546516674475.
   PubMed Web of Science ®Google Scholar
• Álvarez X, Valenzuela M, Tuffet J, et al. Microscopic and histologic evaluation of the regenera® method for the treatment of androgenetic alopecia in a small number of cases. Int J Res Med Health Sci. 2017;2:19–22.
   Google Scholar
• El Samahy MH, Fahmy HM, El Sawaf SI, et al. Lyophilized growth factor intralesional injection in female pattern hair loss: a clinical and trichoscopic study. Dermatol Ther. 2021;34:e14867.
   PubMed Web of Science ®Google Scholar
• Carloni R, Pechevy L, Postel F, et al. Is there a therapeutic effect of botulinum toxin on scalp alopecia? Physiopathology and reported cases: a systematic review of the literature. J Plast Reconstr Aesthet Surg. 2020;73(12):2210–2216. doi: 10.1016/j.bjps.2020.05.035.
   PubMed Web of Science ®Google Scholar
• Nassar A, Abdel-Aleem H, Samir M, et al. Efficacy of botulinum toxin a injection in the treatment of androgenic alopecia: a comparative controlled study. J Cosmet Dermatol. 2022;21(10):4261–4268. doi: 10.1111/jocd.14817.
   PubMed Web of Science ®Google Scholar
• Khattab FM, Rady A, Khashaba SA. Recent modalities in treatment of telogen effluvium: comparative study. Dermatol Ther. 2022;35:e15720.
   PubMed Web of Science ®Google Scholar
• Krefft-Trzciniecka K, Piętowska Z, Nowicka D, et al. Human stem cell use in androgenetic alopecia: a systematic review. Cells. 2023;12:951. doi: 10.3390/cells12060951.
   PubMed Web of Science ®Google Scholar
• Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil®, finasteride®, and adult stem cell-based therapy. Int J Mol Sci. 2020;21:2702. doi: 10.3390/ijms21082702.
   PubMed Web of Science ®Google Scholar
• Budamakuntla L, Loganathan E, Suryanarayana S, et al. Neonatal derived mesenchymal stem cell mesotherapy in androgenetic alopecia: a retrospective observational study and review of literature. Int J Sci Rep. 2015;1(1):32–35. doi: 10.18203/issn.2454-2156.IntJSciRep20150197.
   Google Scholar
• Coban YK. A preliminary result of adipose derived stem cell treatment for female pattern hair loss. J Cosmet Dermatol. 2022;21(3):1303–1304. doi: 10.1111/jocd.14183.
   PubMed Web of Science ®Google Scholar
• Gajjar P, Mehta H, Barvaliya M, et al. Comparative study between mesotherapy and topical 5% minoxidil by dermoscopic evaluation for androgenic alopecia in male: a randomized controlled trial. Int J Trichology. 2019;11(2):58–67. doi: 10.4103/ijt.ijt_89_18.
   PubMedGoogle Scholar
• Hunter N, Sayed K, Hay RA, et al. Comparing the efficacy of mesotherapy to topical minoxidil in the treatment of female pattern hair loss using ultrasound biomicroscopy: a randomized controlled trial. Acta Dermatovenerol Croat. 2019;27:1–7.
   PubMed Web of Science ®Google Scholar
• Shome D, Kapoor R, Doshi K, et al. Comparison of QR 678® & QR678® neo as monotherapy and as combination therapy with 5% minoxidil solution and oral finasteride in the treatment of male androgenetic alopecia—which is better? J Cosmet Dermatol. 2021;20(6):1763–1765. doi: 10.1111/jocd.14154.
   PubMed Web of Science ®Google Scholar
• Shome D, Kapoor R, Vadera S, et al. Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 neo® hair regrowth formulation for the treatment of androgenetic alopecia—a prospective study. J Cosmet Dermatol. 2021;20(10):3299–3307. doi: 10.1111/jocd.14139.
   PubMed Web of Science ®Google Scholar
• Villarreal-Villarreal CD, Boland-Rodriguez E, Rodríguez-León S, et al. Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients. J Eur Acad Dermatol Venereol. 2022;36(7):e570–e572. doi: 10.1111/jdv.18066.
   PubMed Web of Science ®Google Scholar
• Melo DF, de Mattos Barreto T, Plata GT, et al. Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. J Cosmet Dermatol. 2020;19(1):75–77. doi: 10.1111/jocd.12983.
   PubMed Web of Science ®Google Scholar
• Sivagnanam G. Mesotherapy – the french connection. J Pharmacol Pharmacother. 2010;1(1):4–8. doi: 10.4103/0976-500X.64529.
   PubMedGoogle Scholar
• Vedamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol. 2007;73(1):60–62. doi: 10.4103/0378-6323.30661.
   PubMed Web of Science ®Google Scholar
• Konda D, Thappa DM. Mesotherapy: what is new? Indian J Dermatol Venereol Leprol. 2013;79(1):127–134. doi: 10.4103/0378-6323.104689.
   PubMed Web of Science ®Google Scholar
• Alsalhi W, Alalola A, Randolph M, et al. Novel drug delivery approaches for the management of hair loss. Expert Opin Drug Deliv. 2020;17(3):287–295. doi: 10.1080/17425247.2020.1723543.
   PubMed Web of Science ®Google Scholar
• Moftah N, Mubarak R, Abdelghani R. Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study. J Dermatolog Treat. 2021;32(7):827–836. doi: 10.1080/09546634.2019.1708849.
   PubMed Web of Science ®Google Scholar
• In Lee Y, Lee M, Lee S, et al. A permanent hair loss in a patient with hypersensitivity to intralesional triamcinolone injection. Ann Dermatol. 2019;31(2):217–220. doi: 10.5021/ad.2019.31.2.217.
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Arenberger P, Gkalpakiotis S, et al. Scalp melanoma after antihair loss mesotherapy. J Eur Acad Dermatol Venereol. 2018;32(5):e187–e188. doi: 10.1111/jdv.14690.
   PubMed Web of Science ®Google Scholar
• Frioui R, Mokni S, Tabka M, et al. Frontal fibrosing alopecia following beta-blocker injectable mesotherapy: is it more than a simple coincidence? Dermatol Ther. 2022;35:e15206.
   PubMed Web of Science ®Google Scholar
• Melo DF, Saceda-Corralo D, Tosti A, et al. Frontal edema due to mesotherapy for androgenetic alopecia: a case series. Dermatol Ther. 2022;35:e15247.
   PubMed Web of Science ®Google Scholar
• EL-Komy M, Hassan A, Tawdy A, et al. Hair loss at injection sites of mesotherapy for alopecia. J Cosmet Dermatol. 2017;16(4):e28–e30. doi: 10.1111/jocd.12320.
   PubMed Web of Science ®Google Scholar
• Duque-Estrada B, Vincenzi C, Misciali C, et al. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61(4):707–709. doi: 10.1016/j.jaad.2008.11.896.
   PubMed Web of Science ®Google Scholar
• Reguero Del Cura L, De Quintana Sancho A, Rubio LM, et al. Two cases of paradoxical nonscarring alopecia after mesotherapy with dutasteride. Skin Appendage Disord. 2022;8(1):46–48. doi: 10.1159/000518043.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Angioedema-like contact dermatitis caused by mesotherapy with dutasteride. Contact Dermatitis. 2020;83(3):246–247. doi: 10.1111/cod.13585.
   PubMed Web of Science ®Google Scholar